DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $244,080 | +14.1% | 1,017 | +19.8% | 0.01% | +14.3% |
| Q1 2023 | $213,982 | -5.0% | 849 | 0.0% | 0.01% | -12.5% |
| Q4 2022 | $225,342 | -7.3% | 849 | -9.8% | 0.01% | -20.0% |
| Q3 2022 | $243,000 | -35.2% | 941 | -36.5% | 0.01% | -28.6% |
| Q2 2022 | $375,000 | -14.2% | 1,482 | -0.4% | 0.01% | +7.7% |
| Q1 2022 | $437,000 | -57.7% | 1,488 | -52.6% | 0.01% | 0.0% |
| Q4 2021 | $1,032,000 | +101.6% | 3,138 | +86.3% | 0.01% | +8.3% |
| Q3 2021 | $512,000 | -78.4% | 1,684 | -80.9% | 0.01% | -57.1% |
| Q2 2021 | $2,368,000 | +121.7% | 8,820 | +85.7% | 0.03% | +7.7% |
| Q1 2021 | $1,068,000 | +7.2% | 4,749 | +6.0% | 0.03% | 0.0% |
| Q4 2020 | $996,000 | -39.0% | 4,482 | -40.9% | 0.03% | -31.6% |
| Q3 2020 | $1,634,000 | +1.1% | 7,590 | -35.0% | 0.04% | -29.6% |
| Q2 2020 | $1,616,000 | 0.0% | 11,682 | 0.0% | 0.05% | 0.0% |
| Q1 2020 | $1,616,000 | -2.4% | 11,682 | +8.3% | 0.05% | +22.7% |
| Q4 2019 | $1,655,000 | -51.9% | 10,789 | -54.7% | 0.04% | +12.8% |
| Q3 2019 | $3,442,000 | -32.6% | 23,828 | -33.4% | 0.04% | +5.4% |
| Q2 2019 | $5,109,000 | +252.6% | 35,766 | +226.0% | 0.04% | +12.1% |
| Q1 2019 | $1,449,000 | +18.4% | 10,970 | -7.6% | 0.03% | +50.0% |
| Q4 2018 | $1,224,000 | -81.5% | 11,870 | -80.5% | 0.02% | -76.3% |
| Q3 2018 | $6,607,000 | -5.6% | 60,800 | -14.3% | 0.09% | -6.1% |
| Q2 2018 | $6,999,000 | +14.9% | 70,920 | +14.0% | 0.10% | +13.8% |
| Q1 2018 | $6,093,000 | +5.5% | 62,228 | 0.0% | 0.09% | +16.0% |
| Q4 2017 | $5,776,000 | +33.5% | 62,228 | +23.4% | 0.08% | -3.8% |
| Q3 2017 | $4,326,000 | +1.6% | 50,428 | 0.0% | 0.08% | -36.6% |
| Q2 2017 | $4,256,000 | -65.0% | 50,428 | -64.5% | 0.12% | -10.2% |
| Q1 2017 | $12,154,000 | +119.8% | 142,096 | +100.0% | 0.14% | -1.4% |
| Q4 2016 | $5,530,000 | +4.1% | 71,048 | +4.9% | 0.14% | +0.7% |
| Q3 2016 | $5,311,000 | -4.0% | 67,748 | +23.7% | 0.14% | -3.5% |
| Q2 2016 | $5,530,000 | +46.8% | 54,748 | +37.9% | 0.14% | +186.0% |
| Q1 2016 | $3,766,000 | +3.6% | 39,696 | +1.4% | 0.05% | -45.1% |
| Q4 2015 | $3,636,000 | -26.2% | 39,148 | -32.3% | 0.09% | -25.4% |
| Q3 2015 | $4,929,000 | +217.4% | 57,848 | +218.8% | 0.12% | +159.6% |
| Q2 2015 | $1,553,000 | -34.3% | 18,148 | -34.8% | 0.05% | -13.0% |
| Q1 2015 | $2,364,000 | -25.1% | 27,848 | -24.4% | 0.05% | -22.9% |
| Q4 2014 | $3,158,000 | +11.9% | 36,848 | -0.8% | 0.07% | +14.8% |
| Q3 2014 | $2,823,000 | -13.1% | 37,148 | -9.9% | 0.06% | -37.1% |
| Q2 2014 | $3,247,000 | -3.9% | 41,248 | -8.4% | 0.10% | -8.5% |
| Q1 2014 | $3,379,000 | -0.6% | 45,048 | +2.3% | 0.11% | -25.4% |
| Q4 2013 | $3,401,000 | +40.4% | 44,048 | +26.0% | 0.14% | +36.5% |
| Q3 2013 | $2,423,000 | +10.1% | 34,948 | +0.6% | 0.10% | +5.1% |
| Q2 2013 | $2,200,000 | – | 34,748 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |